Sutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022
Current TAP Partner
SOUTH SAN FRANCISCO, Calif., December 10, 2022 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that its research collaborators at Fred Hutchinson Cancer Research Center presented data from the Compassionate Use Program on anti-leukemic activity of STRO-002, a novel folate receptor-α (FR-α) targeting ADC, in pediatric patients with relapsed/refractory CBFA2T3-GLIS2 (CBF/GLIS) acute myeloid leukemia (AML), commonly known as RAM phenotype AML, in an oral presentation at the 64th American Society of Hematology Annual Meeting and Exposition (ASH 2022) in New Orleans, LA.
ASH 2022 Data Highlights:
- 17 pediatric patients were treated with STRO-002 on a compassionate use basis.
- All 17 patients were relapsed/refractory to standard of care AML treatments. The median age of the patients is two years old and the median number of prior therapies is two. Eight of the patients had previously undergone a stem cell transplant (SCT).
- STRO-002 was well-tolerated as a monotherapy agent and in combination with standard of care therapies.
- In the 17 patients treated, Best Overall Response (BOR) includes eight patients with complete remission (CR), of which seven patients were minimal residual disease (MRD) negative.
- 47% of the patients achieved complete remission and 53% of the patients achieved partial response or stable disease.
- Responders were seen in various settings including in patients with or without prior stem cell transplant and in monotherapy or in combination with cytotoxic therapy.